JP2986262B2 - Whitening cosmetics - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a whitening cosmetic having excellent skin safety, an effect of preventing skin inflammation due to ultraviolet rays, and an effect of rapidly lightening dark skin.

[0002]

2. Description of the Related Art The color tone of the skin is changed by the ultraviolet rays and blackened. Blackening is caused by overproduction of melanin, which is produced in melanocytes and passed to epidermal cells, and it is known that tyrosine is oxidized and produced.

Conventionally, vitamin C salts and fatty acid derivatives (Japanese Patent Application Laid-Open No. 1-283208) for preventing the oxidation and preventing the skin from being darkened, stained or freckled, and keeping the original white skin, and hydroquinone monohydrate Whitening cosmetics containing benzyl ether, hydrogen peroxide and the like have been proposed.

However, those containing a vitamin C derivative as described above are often insufficient in storage stability or insufficient in inflammation suppressing effect and whitening effect by ultraviolet rays. Further, those containing hydroquinone monobenzyl ether or the like have an effect of lightening dark skin, but have drawbacks such as a problem in skin safety. As described above, it has been extremely difficult to obtain a storage-stable whitening cosmetic composition having excellent anti-inflammatory effects and whitening effects and high skin safety.

[0005] Therefore, an object of the present invention is to provide a whitening cosmetic which is excellent in inflammation suppressing effect and whitening effect, has high skin safety, and has sufficient storage stability.

[0006]

Means for Solving the Problems In view of such circumstances, the present inventors have conducted intensive studies to improve the disadvantages of the prior art, and as a result, o-coumaric acid-β-D-glucoside (also known as ; Melilot side , 2- (β-glucopyranosi)
It has been found that a composition containing ( loxy) -cinnamic acid ) is a whitening cosmetic composition that satisfies the conditions of excellent inflammation-inhibiting effect, whitening effect, high skin safety, and sufficient storage stability. It was completed.

That is, the present invention provides an o-coumaric acid-β-D-g
A whitening cosmetic comprising Glucose (hereinafter abbreviated as GCA-1), a fir tree comprising GCA-1.
A tyrosinase activity inhibitor
Whitening cosmetics .

GCA used in the whitening cosmetic of the present invention
1 is a known glycoside [Pharmaceutical Magazine, 1968, 88 (1
1), pp. 1467 to p1471], which is obtained by a method known in the art (Melilotus officinalis) (this document).

The amount of the GCA-1 in the whitening cosmetic is preferably 0.001% based on the total amount.
To 5.0% by weight (hereinafter referred to as wt%).

[0010] The whitening cosmetic composition of the present invention can be made into dosage forms such as lotions, emulsions, creams, packs and the like according to a conventional method.

[0011] The whitening cosmetic of the present invention may be appropriately blended with pigments, fragrances, preservatives, surfactants, pigments and the like as long as the object of the present invention is achieved.

[0012]

The present invention will be described below in detail based on examples and comparative examples.

Each of the tests (1) UV erythema suppression test, (2) tyrosinase activity inhibition test, (3) skin color lightness recovery test, (4) whitening practical test, and (5) light patch test described in Examples. The method is as follows.

(1) UV Erythema Inhibition Test On the back skin of 10 Hartley-type guinea pigs whose hair has been removed,
Two times each of the minimum erythema amount of the ultraviolet rays in the UVB region is irradiated at each of two locations. The sample is applied 24 hours before and immediately after the irradiation, the sample application site and the base application site are set, and the erythema state 24 hours later is evaluated according to the criteria shown in Table 1.

[0015]

[Table 1]

(2) Tyrosinase Activity Inhibition Test 1 ml of McClubine buffer (pH 6.8)
g / ml tyrosine solution and each concentration of sample solution,
Preliminary warming is performed at 37 ° C. for 10 minutes. 1 mg /
Add 0.1 ml of tyrosinase (manufactured by Sigma) at a concentration of 3 ml and add 3 ml.
After heating at 7 ° C. for 15 minutes, the absorbance (A) was measured at a wavelength of 475 nm using a spectrophotometer. On the other hand, the absorbance (B) when 0.1 ml of buffer was added instead of tyrosinase, the absorbance (C) when 0.1 ml of buffer was added instead of the sample solution, and the buffer 0 was added instead of the sample solution and tyrosinase. Then, the absorbance (D) of each of the solutions to which .2 ml had been added was measured, and the inhibition rate (%) was calculated according to the following equation.

[0017]

(Equation 1)

(3) Skin lightness recovery test The skin of the upper inner arm of the 20 test subjects was continuously irradiated with the minimum amount of erythema of ultraviolet rays in the UVA and UVB regions for 3 days. The reference lightness (V0 value, V0 'value) of the cream-applied skin was measured. Subsequently, application was performed three times a day for four consecutive weeks, starting irradiation 1,
After 2 or 4 weeks, the skin lightness (Vn value, Vn 'value) of the skin where the sample cream was applied and the base cream was applied was measured.
The skin color recovery was evaluated according to the criteria shown in Table 2.

The lightness of the skin (V value of Munsell display system)
Was calculated from X, Y, and Z values obtained by measurement with a high-speed spectral colorimeter. The evaluation was shown as an average of the evaluation points of 20 test subjects after 4 weeks.

[0020]

[Table 2]

(4) Practical whitening test The left forearm flexion side skin of the forearm flexion skin of 20 test subjects exposed to the sunlight of summer for 3 hours (1.5 hours a day for 2 days) A sample cream and a base cream were applied to the skin on the right forearm flexion side skin once a day in the morning and evening for 13 weeks from the day of sun exposure to the skin and from 7 days after the day of sun exposure to the skin on the right forearm flexion side.

(5) Optical patch test Closed patches were applied to the skin of the flexion side of the forearm of 25 subjects for 24 hours using a patch plate having a diameter of 1.0 cm to which 0.05 g of a sample was applied. For 6 hours (1
(3 hours a day for 2 days).

The evaluation was performed according to the criteria shown in Table 3 below.
The skin condition of each name was evaluated and judged. The judgment result is irradiation 24
After the time, the number is indicated by (±) or more.

[0024]

[Table 3]

Examples 1 to 5 and Comparative Example 1 Two-Phase Lotion In the raw material composition shown in Table 4, active ingredients were blended as shown in Table 4 to prepare a two-phase lotion, and the above-mentioned tests were carried out. .

[0026]

[Table 4]

[0027]

[Table 5]

(1) Preparation method After B component shown in Table 4 was uniformly dissolved in C component,
The component and the C component are uniformly mixed, stirred and dispersed, and then filled into a container. When used, the contents are shaken and dispersed uniformly.

(2) Characteristics Table 5 shows the results of various tests. As shown in Table 5, the two-phase lotions of the present invention of Examples 1 to 5 showed clearly good results in all tests, and no skin irritation occurred in tests on human skin. On the other hand, the sample of Comparative Example 1 was inferior to those of the Examples in various tests.

Examples 6 to 10, Comparative Example 2 Skin Cream Skin cream was prepared by mixing active ingredients as shown in Table 6 in the raw material composition shown in Table 6, and the above-mentioned tests were carried out.

[0031]

[Table 6]

(1) Preparation method The B component shown in Table 6 is mixed with the C component, and the A component and the C component are uniformly heated and dissolved, respectively, to bring the temperature to 80 ° C.
Next, the component C is injected into the component A, mixed with stirring, and then cooled to 30 ° C. with stirring.

Table 5 shows the results of the tests. As shown in Table 5, the skin creams of the present invention of Examples 6 to 10 showed clearly good results in all tests and did not cause skin irritation in tests on human skin. On the other hand, those of Comparative Example 2 were inferior to those of Examples in various tests.

[0034]

As described above, the present invention has no skin irritation, is excellent in suppressing skin inflammation due to ultraviolet rays, is excellent in suppressing the production of melanin pigments, and is also excellent in the effect of rapidly lightening pigmentation of skin. It is an extremely useful whitening cosmetic.

Claims (4)

(57) [Claims] 1. A whitening cosmetic comprising o-coumaric acid-β-D-glucoside . 2. An o-coumaric acid-β-D-glucoside is
Beauty characterized by blending 0.001 to 5.0% by weight
White cosmetics. 3. An o-coumaric acid-β-D-glucoside
A tyrosinase activity inhibitor. 4. The tyrosinase activity inhibitor according to claim 3.
A whitening cosmetic containing.